“…Early in the Ebola epidemic, several patients received a combination of ZMapp antibody and the anti-viral Favipiravir, which led to recovery [78,79]. Reports of enhanced production of proinflammatory cytokines/ chemokines [57,58,80], which are associated with Zika pathogenicity, suggest that anti-inflammatory treatments could ameliorate disease outcomes. We hypothesize that a good candidate for combinational treatment would be one of the immunomodulatory therapeutics, such as AAL-R, that has undergone FDA approval.…”